Edition:
United States

Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

40.20USD
1:52pm EST
Change (% chg)

$-0.66 (-1.62%)
Prev Close
$40.86
Open
$40.24
Day's High
$41.18
Day's Low
$39.49
Volume
67,917
Avg. Vol
191,968
52-wk High
$50.00
52-wk Low
$26.39

Latest Key Developments (Source: Significant Developments)

Arena Pharmaceuticals and United Therapeutics announce global license agreement for Ralinepag
Thursday, 15 Nov 2018 07:00am EST 

Nov 15 (Reuters) - Arena Pharmaceuticals Inc ::ARENA PHARMACEUTICALS AND UNITED THERAPEUTICS ANNOUNCE GLOBAL LICENSE AGREEMENT FOR RALINEPAG.UNITED THERAPEUTICS - UNDER TERMS OF AGREEMENT, ARENA WILL GRANT CO EXCLUSIVE, WORLDWIDE RIGHTS TO DEVELOP, MANUFACTURE & COMMERCIALIZE RALINEPAG.UNITED THERAPEUTICS - ARENA WILL RECEIVE UP TO $1.2 BILLION, INCLUDING UPFRONT PAYMENT OF $800 MILLION & POTENTIAL MILESTONE PAYMENTS TOTALING UP TO $400 MILLION.UNITED THERAPEUTICS - ADDITIONALLY, ARENA WILL RECEIVE LOW DOUBLE-DIGIT TIERED ROYALTIES ON ANNUAL NET SALES OF RALINEPAG.  Full Article

Arena Pharmaceuticals Q3 Loss Per Share $0.70
Wednesday, 7 Nov 2018 04:01pm EST 

Arena Pharmaceuticals Inc ::ARENA PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.70.Q3 REVENUE $3.6 MILLION.Q3 REVENUE VIEW $2.3 MILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.74 -- THOMSON REUTERS I/B/E/S.  Full Article

Arena Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
Wednesday, 21 Mar 2018 07:07pm EDT 

March 21 (Reuters) - Arena Pharmaceuticals Inc ::ARENA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 8.50 MILLION COMMON SHARES PRICED AT $41.50PER SHARE.  Full Article

Arena Pharmaceuticals Reports Positive Phase 2 Results For Oasis Trial For Etrasimod
Monday, 19 Mar 2018 04:01pm EDT 

March 19 (Reuters) - Arena Pharmaceuticals Inc ::ARENA PHARMACEUTICALS REPORTS POSITIVE PHASE 2 RESULTS FOR THE OASIS TRIAL FOR ETRASIMOD IN PATIENTS WITH ULCERATIVE COLITIS.HIGH DOSE ETRASIMOD GROUP ACHIEVED STATISTICALLY SIGNIFICANT IMPROVEMENT IN CLINICAL REMISSION IN STUDY.TRIAL MET PRIMARY, SECONDARY ENDPOINTS WITH STATISTICAL SIGNIFICANCE FOR PATIENTS GETTING HIGH DOSE ETRASIMOD FOR 12 WKS.ETRASIMOD WAS WELL TOLERATED, HAD FEWER PATIENTS WITH SERIOUS ADVERSE EVENTS VERSUS PLACEBO IN STUDY.IMPACT ON HEART RATE, ATRIOVENTRICULAR (AV) CONDUCTION LOW IN STUDY WITH NO DISCONTINUATIONS RELATED TO BRADYCARDIA OR AV BLOCK.NO INCREASES IN LIVER FUNCTION TESTS VERSUS PLACEBO, NO REPORTS OF MACULAR EDEMA OR PULMONARY FUNCTION TEST ABNORMALITIES IN STUDY.INTENDS TO INITIATE PHASE 3 PROGRAM IN ULCERATIVE COLITIS.  Full Article

Arena Pharmaceuticals Q4 Loss Per Share $0.35
Wednesday, 14 Mar 2018 08:00am EDT 

March 14 (Reuters) - Arena Pharmaceuticals Inc ::ARENA PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS.Q4 REVENUE $15.4 MILLION.Q4 REVENUE VIEW $7.6 MILLION -- THOMSON REUTERS I/B/E/S.Q4 LOSS PER SHARE $0.35.Q4 EARNINGS PER SHARE VIEW $-0.59 -- THOMSON REUTERS I/B/E/S.‍AT DECEMBER 31, 2017, COMPANY'S CASH, CASH EQUIVALENTS AND INVESTMENTS BALANCE WAS $271.3 MILLION​.  Full Article

Arena Pharma, Everest Medicines Enter Into Development And Commercialization Partnership For Ralinepag And Etrasimod In China
Tuesday, 5 Dec 2017 08:30am EST 

Dec 5 (Reuters) - Arena Pharmaceuticals Inc ::ARENA PHARMACEUTICALS AND EVEREST MEDICINES ENTER INTO DEVELOPMENT AND COMMERCIALIZATION PARTNERSHIP FOR RALINEPAG AND ETRASIMOD IN CHINA.ARENA PHARMACEUTICALS INC - C-BRIDGE CAPITAL HAS INVESTED $50 MILLION TO FUND EVEREST MEDICINES LIMITED.ARENA PHARMACEUTICALS - AS PER AGREEMENT, CO WILL RECEIVE AN UPFRONT PAYMENT OF $12 MILLION.ARENA PHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, ARENA IS ELIGIBLE TO RECEIVE UP TO $212 MILLION IN DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS.  Full Article

Arena Pharmaceuticals reports Q3 loss per share $0.86
Tuesday, 7 Nov 2017 04:01pm EST 

Nov 7 (Reuters) - Arena Pharmaceuticals Inc ::Arena Pharmaceuticals provides corporate update and reports third quarter 2017 financial results.Q3 loss per share $0.86.Q3 revenue $7.9 million.Q3 revenue view $5.5 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.67 -- Thomson Reuters I/B/E/S.Arena Pharmaceuticals Inc - ‍expect to complete full enrollment for etrasimod phase 2 study in ulcerative colitis this week​.Arena Pharmaceuticals Inc - ‍initiated etrasimod phase 2 study in primary biliary cholangitis​.  Full Article

Arena Pharmaceuticals Q2 loss per share $0.77
Monday, 7 Aug 2017 04:01pm EDT 

Aug 7 (Reuters) - Arena Pharmaceuticals Inc :Arena Pharmaceuticals provides corporate update and reports second quarter 2017 financial results.Q2 revenue $6.5 million versus I/B/E/S view $5.5 million.Q2 loss per share $0.77.Q2 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.Arena Pharmaceuticals - ‍at June 30, cash and cash equivalents totaled $130.8 million; about 31.8 million shares of arena common stock were outstanding​.  Full Article

Arena Pharmaceuticals says public offering of 6.25 mln common shares priced at $24 per share
Wednesday, 12 Jul 2017 08:11pm EDT 

July 12 (Reuters) - Arena Pharmaceuticals Inc :Arena Pharmaceuticals announces pricing of public offering of common stock.Says public offering of 6.25 million common shares priced at $24.00per share.Gross proceeds from offering are expected to be $150.0 million.  Full Article

Arena Pharmaceuticals says has cash and cash equivalents as of June 30 of $130.8 mln
Tuesday, 11 Jul 2017 05:28pm EDT 

July 11 (Reuters) - Arena Pharmaceuticals Inc :Arena Pharmaceuticals - Cash and cash equivalents as of June 30, 2017 of $130.8 million, which includes about $0.2 million of cash held by beacon discovery.  Full Article

Arena Pharma soars on deal with United Therapeutics for hypertension drug

Shares of Arena Pharmaceuticals Inc jumped nearly 30 percent after the drug developer sold rights to develop and sell its hypertension treatment to United Therapeutics Corp, fetching it $800 million in an upfront payment.